Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

95.10 +0.47 (+0.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corp

< Previous 1 2 3 4 5 6 Next >
Blueprint Medicines's Return On Capital Employed Overview
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
16 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
FDA Removes Partial Clinical Hold From Blueprint Medicines' Cancer Study
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview For Blueprint Medicines
Via Benzinga
Analyst Ratings for Blueprint Medicines
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer Patients
Via Benzinga
Roche Decides To Terminate Cancer Treatment Pact With Blueprint Medicines
Via Benzinga
FDA Slaps Partial Clinical Hold On Blueprint Medicines' Early-Stage Solid Tumor Study
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... 
Via Benzinga
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings: 
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Blueprint Medicines (NASDAQ:BPMC) reported its Q3 earnings results on Tuesday, November 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Needham raised Uber Technologies, Inc. (NYSE: UBER) price target from $52 to $54. Needham analyst Bernie McTernan maintained the stock with a Buy rating. Uber shares fell 0.3% to $29.65 in pre-market... 
Via Benzinga
NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- Certain directors of Blueprint Medicines Corporation are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter: 
Via Benzinga
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 08/30/2022 -- Blueprint Medicines Corporation is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
What 14 Analyst Ratings Have To Say About Blueprint Medicines
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter: 
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Gainers GigaCloud Technology Inc (NASDAQ: GCT) shares jumped 206% to close at $48.01 on Friday on continued volatility following the company's IPO on Thursday. 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.